OR WAIT null SECS
October 14, 2020
Shimadzu, has opened a new branch office in Copenhagen, Denmark.
Cambrex has completed the expansion of its solid form screening and crystallization process development facility in Edinburgh, Scotland.
Oxular has been granted rare pediatric disease and orphan drug designations by the US FDA for its proprietary drug, OXU-003.
October 13, 2020
The company will supply its LIMS to the Walter Reed Army Institute of Research (WRAIR) to support vaccine production programs for COVID-19 at WRAIR’s pilot bioproduction facility.
Virtual Touring allows companies to inspect and visit vendor and contract partner sites remotely during the COVID-19 pandemic.
October 12, 2020
The companies are entering into an agreement for the late-stage development and large-scale manufacturing of AZD7442, AstraZeneca’s investigational product for treatment and prevention of COVID-19.
The expansion has doubled Cambrex’s footprint to 15,000 ft2, including an added 3500 ft2 of laboratory space.
October 09, 2020
Rentschler will handle the downstream processing to provide highly purified drug substance at its headquarters in Laupheim, Germany.
The partnership aims to provide a platform of hiPSC-based assays, drug discovery technologies, high-throughput screening, and high-content screening.
October 08, 2020
Purdue University’s Continuity Pharma received a $1.5-million grant from DARPA to develop continuous manufacturing technology for generic drug products.